Impact of dry eye disease and treatment on quality of life

被引:197
作者
Friedman, Neil J. [1 ,2 ]
机构
[1] Midpeninsula Ophthalmol Med Grp, Palo Alto, CA 94304 USA
[2] Stanford Univ, Sch Med, Stanford, CA 94305 USA
关键词
artificial tears; cyclosporine; dry eye syndrome; hydroxypropyl cellulose; keratoconjunctivitis sicca; FUNCTIONAL VISUAL-ACUITY; OCULAR SURFACE; TOPICAL CYCLOSPORINE; PUNCTAL OCCLUSION; PREVALENCE; HEALTH; SYMPTOMS; EFFICACY; VALIDITY;
D O I
10.1097/ICU.0b013e32833a8c15
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose of review Recent increased awareness of dry eye disease (DED) by both clinicians and patients has been accompanied by improved recognition that it is a chronic disorder often requiring long-term management. DED, frequently associated with symptoms of discomfort and visual disturbance, also impairs quality of life (QoL), including aspects of physical, social, and psychological functioning. This review summarizes the available research on the impact of DED and its treatment on measures of QoL. Recent findings A relative dearth of data supporting the effectiveness of DED treatments as assessed by QoL measures exists. Both cyclosporine ophthalmic emulsion 0.05% and hydroxypropyl cellulose ophthalmic inserts have been associated with improvements in Ocular Surface Disease Index scores, a disease-specific measure of QoL, and with enhancement of patients' ratings regarding their ability to perform activities of daily living. Summary Because there is a lack of concordance between symptoms and diagnostic measures of DED, QoL measures provide clinicians a valuable tool for assessing the burden of disease as well as response to treatment. Such measures should be employed in clinical practice and in future trials of treatment modalities.
引用
收藏
页码:310 / 316
页数:7
相关论文
共 53 条
[1]   Silicone versus collagen plugs for treating dry eye: Results of a prospective randomized trial including lacrimal scintigraphy [J].
Altan-Yaycioglu, R ;
Gencoglu, EA ;
Akova, YA ;
Dursun, D ;
Cengiz, F ;
Akman, A .
AMERICAN JOURNAL OF OPHTHALMOLOGY, 2005, 140 (01) :88-93
[2]   The FDA guidance for industry on PROs: the point of view of a pharmaceutical company [J].
Arpinelli, Fabio ;
Bamfi, Francesco .
HEALTH AND QUALITY OF LIFE OUTCOMES, 2006, 4 (1)
[3]   Ophthalmologist Perceptions Regarding Treatment of Moderate-to-Severe Dry Eye: Results of a Physician Survey [J].
Asbell, Penny A. ;
Spiegel, Scott .
EYE & CONTACT LENS-SCIENCE AND CLINICAL PRACTICE, 2010, 36 (01) :33-38
[4]   Characterization of ocular surface symptoms from optometric practices in North America [J].
Begley, CG ;
Chalmers, RL ;
Mitchell, GL ;
Nichols, KK ;
Caffery, B ;
Simpson, T ;
DuToit, R ;
Portello, J ;
Davis, L .
CORNEA, 2001, 20 (06) :610-618
[5]  
Bron AJ, 2007, OCUL SURF, V5, P108
[6]   Value-Based Medicine, Comparative Effectiveness, and Cost-effectiveness Analysis of Topical Cyclosporine for the Treatment of Dry Eye Syndrome [J].
Brown, Melissa M. ;
Brown, Gary C. ;
Brown, Heidi C. ;
Peet, Jonathan ;
Roth, Zachary .
ARCHIVES OF OPHTHALMOLOGY, 2009, 127 (02) :146-152
[7]   SmartPlug in the management of severe dry eye syndrome [J].
Chen, Simon X. ;
Lee, Graham A. .
CORNEA, 2007, 26 (05) :534-538
[8]   Topical Ophthalmic Cyclosporine: Pharmacology and Clinical Uses [J].
Donnenfeld, Eric ;
Pflugfelder, Stephen C. .
SURVEY OF OPHTHALMOLOGY, 2009, 54 (03) :321-338
[9]   Treatment of Dry Eye Disease by the Non-Ophthalmologist [J].
Foulks, Gary N. .
RHEUMATIC DISEASE CLINICS OF NORTH AMERICA, 2008, 34 (04) :987-+
[10]  
Gayton JL, 2009, CLIN OPHTHALMOL, V3, P405